07:14 AM EST, 12/16/2024 (MT Newswires) -- Merck & Co ( MRK ) said Monday that its anti-PD-1 therapy, KEYTRUDA, has been approved by the National Medical Products Administration in China in combination with chemotherapy to treat certain patients with non-small cell lung cancer.

KEYTRUDA was previously approved in combination with chemotherapy in the US in October 2023 based on results from the KEYNOTE-671 trial.

The trial showed significant improved overall survival, reducing the risk of death by 28% versus placebo plus chemotherapy, as well as improved event-free survival, reducing the risk of disease recurrence, progression or death by 42%, the company said.